#ICYMI: $CLDI's CEO Eric Poma, Ph.D. spoke with BioPharma Boardroom about the #RedTail platform, CLD-401 and Calidi’s approach to reaching primary and metastatic tumors.
In a recent Talking Biotech episode, $CLDI's CEO & Director Eric Poma, Ph.D. discusses Calidi’s systemic #oncolyticvirus platform and CLD-401, designed to avoid immune clearance and selectively replicate in tumor cells.
In a interview with @RedChip Eric Poma, Ph.D. discusses $CLDI's #RedTail platform & CLD-401, designed to target and lyse tumor cells while delivering an IL-15 superagonist to help activate an anti-cancer immune response.
$CLDI shared preclinical #RedTail data at @myESMO's #ESMO26. A single dose of CLD-401 achieved complete tumor eradication in 80% of mice, while the in situ TCE platform generated ~10 ng/mL of EpCAM-targeted TCE directly in tumors after IV delivery.
Advancing a new generation of cancer therapies at $CLDI. Targeted delivery. Immune activation. Real impact. The future of cancer care is bigger than one approach.